Clinical Study to Evaluate the Efficacy of an Anti-Fungal Supplement

Status Active, not recruiting

Clinical Trial Summary

This is a virtual, double-blind, two-arm, randomized, placebo-controlled clinical trial that will last 12 weeks. Participants will take the CanXida Remove Candida Cleansing Formula RMV or a placebo product daily and complete questionnaires at Baseline, Week 6, and Week 12. Candida microbiome testing will be conducted via stool sample at Baseline and Week 12. The participants will all be blinded to the name of the test brand.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06146504
Study type	Interventional
Source	CanXida
Contact
Status	Active, not recruiting
Phase	N/A
Start date	November 30, 2023
Completion date	February 28, 2024

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03641131` - Ampholipad Real-World Data in Taiwan
Completed	`NCT03203551` - Clinical and Laboratorial Evaluation of the Desinfection Solutions in Candida Species From Total Prostheses and Palate of Total Edentulous.	N/A
Not yet recruiting	`NCT03666195` - The Anti-microbial Effect of Titanium Dioxide Nano Particles in Complete Dentures Made for Edentulous Patients	N/A
Completed	`NCT01495039` - Antifungal Prophylaxis in Intensive Care Unit (ICU) Patients	Phase 4
Completed	`NCT04935463` - Mucormycosis in COVID-19
Completed	`NCT05720728` - Research of New Serological Markers for the Diagnosis and Monitoring of Candidaemia in Hospitalized Patients
Completed	`NCT03140748` - Kinetics of Serum β-D-glucan During Peritonitis With Candida in Resuscitation	N/A
Completed	`NCT01743690` - The Use of Probiotics in Patients With Symptomatic Oral Lichen Planus	N/A
Completed	`NCT03630770` - Effect of Medium Chain Triglyceride Intake on Colonization of Preterm Infants With Candida	Phase 1
Recruiting	`NCT05908682` - Safety of Pregnant Subjects Exposed to Ibrexafungerp Including Infant Outcomes
Not yet recruiting	`NCT05761197` - Oropharyngeal Candidiasis (OPC) and S-ECC
Recruiting	`NCT05225493` - HIV Indicator Diseases in Hospital and Primary Care
Completed	`NCT04148287` - An Open-label Study of APX001 for Treatment of Patients With Candidemia/Invasive Candidiasis Caused by Candida Auris	Phase 2